Zobrazeno 1 - 10 of 16 pro vyhledávání: '"Marie‐Rose B. S. Crombag"'
1
Akademický článek
Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort
Autor: Aurelia H. M. deVries Schultink, Marie‐Rose B. S. Crombag, Erik vanWerkhoven, Hans‐Martin Otten, Andre M. Bergman, Jan H. M. Schellens, Alwin D. R. Huitema, Jos H. Beijnen
Publikováno v: Cancer Medicine, Vol 8, Iss 4, Pp 1406-1415 (2019)
Abstract The incidence of neutropenia in metastatic castration‐resistant prostate cancer (mCRPC) patients treated with docetaxel has been reported to be lower compared to patients with other solid tumors treated with a similar dose. It is suggested
Externí odkaz: https://doaj.org/article/915cd825bb7749d88d3c80c0290c56dc
Zobrazit plný text záznamu
2
Akademický článek
The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients
Autor: Leni van Doorn, Marie-Rose B. S. Crombag, Hánah N. Rier, Jeroen L. A. van Vugt, Charlotte van Kesteren, Sander Bins, Ron H. J. Mathijssen, Mark-David Levin, Stijn L. W. Koolen
Publikováno v: Pharmaceuticals, Vol 14, Iss 1, p 47 (2021)
Changes in body composition are associated with chemotherapy-related toxicities and effectiveness of treatment. It is hypothesized that the pharmacokinetics (PK) of chemotherapeutics may depend on body composition. The effects of body composition on
Externí odkaz: https://doaj.org/article/44294eeb4ea947efa337cb15104e1388
Zobrazit plný text záznamu
3
Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction
Autor: Elisa Proietti, Renske W M Pauwels, Christien J van der Woude, Michael Doukas, Lindsey Oudijk, Maikel P Peppelenbosch, Ursula Grohmann, Marie-Rose B S Crombag, Annemarie C de Vries, Gwenny M Fuhler
Publikováno v: Inflammatory Bowel Diseases. Oxford University Press
Background Ustekinumab (UST), which targets p40/interleukin (IL)-23 and IL-12, is an effective treatment for Crohn’s disease (CD). Therapeutic drug monitoring may optimize UST posology. The aim of this study was to investigate UST and IL-23 serum a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76fe4e87da69821ddd62e580843fb12f
https://doi.org/10.1093/ibd/izac169
Zobrazit plný text záznamu
4
Is age just a number? A population pharmacokinetic study of gemcitabine
Autor: René J. Boosman, Marie-Rose B. S. Crombag, Nielka P. van Erp, Jos H. Beijnen, Neeltje Steeghs, Alwin D. R. Huitema
Publikováno v: Cancer Chemotherapy and Pharmacology, 89, 697-705
Cancer Chemotherapy and Pharmacology, 89(5), 697-705. Springer-Verlag
Cancer Chemotherapy and Pharmacology, 89, 5, pp. 697-705
Item does not contain fulltext PURPOSE: Pharmacokinetic exposure to gemcitabine and its metabolite, 2',2'-difluorodeoxyuridine (dFdU), might be altered in elderly compared to their younger counterparts. It is unknown if age-based dose adjustments are
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d90018cf7c63cb55e0d1af4da1290c8
http://hdl.handle.net/2066/251183
Zobrazit plný text záznamu
5
Is age just a number? A population pharmacokinetic study of gemcitabine
Autor: René J, Boosman, Marie-Rose B S, Crombag, Nielka P, van Erp, Jos H, Beijnen, Neeltje, Steeghs, Alwin D R, Huitema
Publikováno v: Cancer chemotherapy and pharmacology. 89(5)
Pharmacokinetic exposure to gemcitabine and its metabolite, 2',2'-difluorodeoxyuridine (dFdU), might be altered in elderly compared to their younger counterparts. It is unknown if age-based dose adjustments are necessary to reduce the development of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6be786fbb7a5ddf49767255ec0f9822f
https://pubmed.ncbi.nlm.nih.gov/35426526
Zobrazit plný text záznamu
6
Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease
Autor: R W M Pauwels, Marie-Rose B S Crombag, Gwenny M. Fuhler, Christien J. van der Woude, Elisa Proietti, Maikel P. Peppelenbosch, Lindsey Oudijk, Ursula Grohmann, Annemarie C. de Vries
Publikováno v: Inflammatory Bowel Diseases, 27(11), 1813-1820. Oxford University Press
Inflammatory Bowel Diseases
Background The association between vedolizumab (VDZ) exposure and treatment response is unclear and seems insufficiently explained by serum levels. The aim of this study was to assess the correlation between VDZ concentrations in serum and intestinal
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19f75398f0938ab4173ca49a8ccbd04c
https://pure.eur.nl/en/publications/71e20081-1cb5-4327-8627-828f04bc01bc
Zobrazit plný text záznamu
7
Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study
Autor: Anoek van Straten, Nielka P. van Erp, Alwin D. R. Huitema, Marie-Rose B S Crombag, Andries M. Bergman, Jos H. Beijnen, Thomas P. C. Dorlo, Ellen van der Pan
Publikováno v: Pharmaceutical Research, 36(12). Springer New York
Pharmaceutical Research, 36(181). Springer New York LLC
Pharmaceutical Research, 36, 12
Pharmaceutical Research, 36
BACKGROUND: Docetaxel is commonly used in elderly patients, who are frequently diagnosed with prostate cancer. Although previous studies revealed no clinically relevant impact of older age on docetaxel pharmacokinetics (PK), this may be masked by ind
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bafd697eadf35b6711fae943fce8c31f
https://dspace.library.uu.nl/handle/1874/389842
Zobrazit plný text záznamu
8
Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?
Autor: Stijn L.W. Koolen, Nielka P. van Erp, Ron H.J. Mathijssen, Thomas P. C. Dorlo, Marie-Rose B S Crombag, Sophie Wijngaard, Jos H. Beijnen, Alwin D. R. Huitema, Markus Joerger
Publikováno v: Pharmaceutical Research, 36(12):163. Springer New York
Pharmaceutical Research, 36
Pharmaceutical Research, 36, 12
Pharmaceutical Research, 36(12). Springer New York
Pharmaceutical Research, 36(12). Springer New York LLC
Purpose: There is ongoing concern regarding increased toxicity from paclitaxel in elderly patients, particularly of severe neutropenia. Yet, data so far is controversial and this concern is not supported by a clinically relevant age-dependent differe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7904b264257684f3d6a38f5748e3b8a
https://pure.eur.nl/en/publications/e144242d-e111-4d2b-8a55-7c6512fff05f
Zobrazit plný text záznamu
10
Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study
Autor: Ron H.J. Mathijssen, Jan H.M. Schellens, Aurelia H. M. de Vries Schultink, Markus Joerger, Marie-Rose B S Crombag, Thomas P. C. Dorlo, Sophie Wijngaard, Stijn L.W. Koolen, Alwin D. R. Huitema, Jos H. Beijnen, Nielka P. van Erp
Publikováno v: Pharmaceutical Research, 36(2):33. Springer New York
Pharmaceutical Research, 36, 2
Pharmaceutical Research, 36
Pharmaceutical Research, 36(2). Springer New York LLC
Pharmaceutical Research, 36(2). Springer New York
Purpose: Limited available data suggest that older patients are more prone to develop paclitaxel-induced toxicity than their younger peers. It remains unclear whether this is related to age-dependent pharmacokinetics (PK) of paclitaxel. Primary objec
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9e404eecabc63644ec7140112323f5d
https://pure.eur.nl/en/publications/6c0becb1-1fbd-4370-906d-beab6e7b1f76
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje